They found a 5 mm nodule on my scan. Now what?

Transcript

Welcome to the sofidex Health Drive podcast series. Today we are talking about the small spot on a scan that nobody went looking for, and the one word on the report that can take over your whole week: nodule. Maybe you had a scan for something else entirely, a kidney stone or a pain that would not settle. A few days later the report appeared in an app, and one line near the bottom mentioned your lung. You read it before anybody rang you, and by midnight you had searched for it.

And what you found tends to come in two unhelpful kinds. There are pages that treat every spot as a cancer waiting to be named, and there is the busy appointment where somebody says it is probably nothing and moves on. You are in very large company, because nodules turn up on nearly a third of chest scans, and the great majority of them turn out to be harmless.

So we want to ask a different question from the one that kept you awake. Not only whether this is cancer, because at that size it very rarely is, but how much looking is actually worth it, and who gets to decide. We will go through what a nodule actually is, and why the size matters far more than the word. We will look at the guidance radiologists use, why its line moved, and why it deliberately leaves room for you to choose. And we will get to the conversation with your doctor, including the questions that make it go better.

If you are waiting on a result right now, nothing here replaces the plan your own team has made, and nothing in it is a reason to skip a scan you have been offered. One thing before we start. This is health information, not medical advice, and nothing in it is a substitute for talking to your own doctor about your own treatment. What we can tell you is where all of it came from — 9 published sources, all listed with the episode. I want to do this one through a single person, if that's alright. Not a real patient. Somebody we're making up, so we can follow her all the way through. Call her Helen. She's fifty-eight. A month ago she went to A&E with a pain in her side, and it turned out to be a kidney stone. They scanned her. The stone passed. And three days later the report turned up in the app on her phone, before anybody had rung her.

And most of that report was about her kidney. Which was fine. But near the bottom there was one line about her lung. Five millimetre solid nodule, right lower lobe. That's it. No explanation. No plan. Just those words, on a phone, at about eleven at night. And that line is the whole episode. Because of what the word nodule did to her. It turned into the word cancer somewhere between her eyes and her brain. That isn't Helen being dramatic. It's close to universal. Researchers sat groups of people with nodules down and asked them what that first moment was like. In that study, almost all patients immediately assumed that they had cancer when first told about the nodule. So whatever Helen's feeling, she's in very large company.

So she's lying awake, and she's typed it into her phone, and she's three pages deep. Where do you want to start with her? Because I'd guess she wants the ending first.

She does. Everybody does. But I'd start with the word, because the word is doing most of the damage. Then the size. Then the part nobody tells patients, which is that she gets a say. I'll say one thing up front though, so she isn't holding her breath for twenty minutes. At five millimetres, the chance this is cancer is very small. Not zero. Very small. And we'll get to the exact number, because the number turns out to matter more than any reassurance.

Alright. The word, then. Because nodule sounds like a medical term for something specific and sinister. Like a growth. What is it actually describing?

Almost nothing. Which is the surprising part. Nodule just means a small, roundish spot. It's a description of a shape on a picture. Not a diagnosis. So a radiologist looks at the scan, sees a little round patch that's brighter than the lung around it, and nodule is the word for that. And most of the time, what it's made of is dull. Old scarring. A tiny lymph node. A patch where the lung healed after an infection that Helen may never have noticed. The JAMA review is blunt about this: at least ninety-five per cent of all pulmonary nodules identified are benign, most often granulomas or intrapulmonary lymph nodes.

Granulomas. So that's a scar, basically. A healed-over spot. But if most of them are that, why does it end up on a report at all? Why tell her?

Because nobody can tell from one picture which of the other five per cent it might be. And because scans see a great deal now. The same review says nodules are detected on approximately thirty per cent of CT images of the chest. Nearly a third. And Helen's wasn't even a chest scan. It was her abdomen. But the bottom of her lungs just happened to be in the picture. And that's what the word incidental means on a report. It isn't a symptom. It's a side effect of the camera.

A side effect of the camera. But she's still got a number staring at her. Five millimetres. Is that big? Small? Help me picture it.

Small. Think of a peppercorn, or a little less. And the way it's measured is worth knowing, because it tells you how exact that number really is. The review's footnote puts it like this: dimensions are the average of long and short axes, rounded to the nearest millimetre. So five millimetres could be a slightly oval thing, four one way and six the other. It's a rounded figure. For a tiny, irregular object. On a grey picture. And that matters later. Because if she ever has another scan, a fair question for the radiologist is whether a small change is real growth or just the measuring.

Okay. Peppercorn-sized, and roughly measured. But the question Helen actually typed into her phone at midnight was the obvious one. What are the chances it's cancer?

And that has a real answer, which surprises people. At this size, it's very small. The JAMA review puts it plainly: the probability of malignancy is less than one per cent for all nodules smaller than six millimetres. Less than one in a hundred. Helen came in thinking about it like a coin toss. Cancer, or not cancer. Two outcomes, so it feels like even odds. It isn't. It's more like ninety-nine and a bit against. Which is why the whole system is built around size. Below six millimetres, the risk is low enough that the main question changes. So it stops being how do we find out what this is. And it becomes whether anybody needs to look again at all. That can sound like nobody's taking you seriously. But it's the opposite. It's good news.

So where does six come from? Because Helen's at five, and that feels uncomfortably close to a line. Like she's one millimetre away from being a different kind of patient.

It does feel like that. But it helps to know the line was drawn on purpose, and that it moved. The Fleischner Society is an international group of chest specialists, and theirs is the guidance written for nodules nobody went looking for. Like Helen's. And they revised it in twenty seventeen. Their own summary says the minimum threshold size for routine follow-up has been increased. And the review that walks through that update says the minimal threshold size for follow-up went from four to six millimetres. Under the older version, Helen's spot would have sat on the other side of the line. Then the line moved, and now it doesn't. Not because her spot changed. Because the line was redrawn. And the review also explains that the six millimetre mark is set where the cancer risk estimate reaches one per cent or greater.

The line was redrawn. So for someone like Helen, under it, what does the guidance actually tell her doctor to do? Is it just: forget about it?

For some people, more or less, yes. And this is where Helen herself comes in, not just her spot. The guidance splits people into lower risk and higher risk. The review sets out the rule for a single solid nodule that size: nodules smaller than six millimetres generally don't require follow-up in low-risk patients. No scan. Nothing. And for high-risk patients, the Fleischner table offers an optional CT at twelve months. Optional. That word's doing real work. Because it means the people who wrote the guidance aren't convinced the second scan helps everyone. So they hand the choice to Helen and her doctor. Which raises the question everybody skips. Is Helen low risk, or high risk?

Right, so which is she? She's fifty-eight. She smoked through her twenties and into her thirties, and stopped when she was pregnant with her second. That's over twenty years ago now.

And that's exactly the kind of history that can put someone in the higher-risk group, even this long after stopping. The review lists the patient factors: age, sex, race, family or smoking history were found to be associated with a higher risk of developing lung cancer. Helen's age counts. Her past smoking counts. So she's likely in the higher-risk column, which means a scan in a year is on the table. Not required. Offered. Her risk is still very low in absolute terms. High risk here means higher than somebody who's twenty-five and never smoked. It doesn't mean high. It means the line between scan and no scan is close enough that what she wants actually matters.

What she wants. That's the bit I didn't expect. I'd assumed the guideline tells the doctor what to do, and the patient goes along with it.

Most people assume that. But with small nodules the guidance goes out of its way to do the opposite. The Fleischner summary says recommended follow-up intervals are now given as a range rather than as a precise time period to give radiologists, clinicians, and patients greater discretion to accommodate individual risk factors and preferences. Patients. Preferences. It's written in. And the American chest physicians land in the same place. Their guideline says people with nodules should be managed by estimating the probability of malignancy, evaluating the risks of the options, and eliciting their preferences. So Helen isn't being fobbed off if her doctor asks what she'd like. That's the guidance working exactly as designed. But the trouble is that nobody tells patients this. So when the question comes, it can sound like the doctor doesn't know what to do. They do. They know the risk is small enough for the choice to be hers.

So she's choosing between scanning again in a year and leaving it alone. Why wouldn't you just scan? Surely more information is always better?

That's the instinct, and it's worth taking apart. Because looking has costs. The first is radiation. A CT isn't nothing. Then there's what scans find. Look at a lung closely, and you'll often find something else. Another little spot. And each of those comes with its own follow-up. And then there's the waiting. And the big American evidence review on lung screening lists the harms plainly: false-positive results leading to unnecessary tests and invasive procedures, overdiagnosis, incidental findings, and increases in distress. Distress is on that list. It's counted as a harm, not a feeling. And the review says radiation-induced cancers happen, but rarely. So the question isn't more information versus less. It's whether what a second scan might tell Helen is worth what it might cost her.

Unnecessary tests and invasive procedures. That sounds dramatic for somebody with a peppercorn. How often does a false alarm actually end in somebody being cut or needled?

Not often, but often enough to count. The same review gives a figure from the big American screening trial. For every thousand people screened in that trial, false-positive results led to seventeen invasive procedures, and fewer than one person had a major complication. That's a small number. But it isn't zero, and those were people who'd been told they were fine before anybody looked.

False positives. That's the phrase I keep hearing. But Helen wasn't screened. She had a kidney stone. Does any of the screening evidence even apply to her?

Partly. A lot of what's been measured about small nodules comes from screening studies, because those are the people who get scanned year after year and followed for a long time. So we borrow from them. And the big American trial is a useful mirror for Helen. In that trial, a scan counted as positive if it showed a nodule at least four millimetres across. Helen's five would have counted. So if she'd been in that trial instead of in A&E, she'd have been told her result was positive. Same spot. Same size. A much more frightening word.

Hang on. So the exact spot that's keeping her awake would have been called a positive result? That sounds like the worst possible thing to be told.

It would have sounded like it. But positive, in that trial, meant something much narrower than it sounds. It meant worth another look. Not likely to be cancer. And across the whole trial, ninety-six point four per cent of the positive low-dose CT results were false positives. Ninety-six in a hundred. Not cancer. So by the standards of that trial, Helen's spot is exactly the kind of finding that almost always turns out to be nothing. Which tells you something about words like positive on a report. They describe a decision about looking. They don't describe you.

Ninety-six in a hundred. Okay. But that leaves four in a hundred, and four is still four people. What makes a spot more likely to be one of those?

Some of the predictors are fairly intuitive. And a couple aren't. A large Canadian study built a model from thousands of nodules found on screening scans. The predictors of cancer in the model included older age, female sex, family history, emphysema, larger nodule size, a position in the upper lobe, and spiculation. Spiculation means spiky edges. Little fingers reaching out from the spot, instead of a smooth outline. And upper lobe means the top of the lung. Now look at Helen. Her report says right lower lobe. And it says solid. It doesn't mention spikes, and spikes are something she can simply ask about. So on the features of the spot itself, she's on the reassuring side of most of them. She's a woman, and she's not young, and those push slightly the other way. Which is fine. It's a model.

You said a couple of them aren't intuitive. Which ones?

The one I like is the number of spots. You'd think more nodules would be worse. Several spots. More chances. More worry. But in that study it went the other way. In both data sets, the mean and median nodule counts were lower when cancer was present. So people with cancer tended to have fewer nodules, not more. My guess at why — and it's a guess, not a finding — is that lots of little spots often means something widespread and harmless. Helen has one. So that cuts slightly against her. And I'm saying that on purpose, because I don't want this to sound like everything points one way. It doesn't. It mostly points one way.

It mostly points one way. And there was another word on her report. Solid. Why would a radiologist bother writing that down?

Because nodules come in different textures, and they're handled differently. The JAMA review sorts them into small solid, larger solid, and subsolid. And subsolid is then split into ground glass, which looks like a faint haze, and part solid, which is a haze with a denser bit inside it. And Helen's is solid. But ground glass spots behave differently. And the review says a malignant nodule that's entirely ground glass in appearance is typically slow growing. So those get watched for longer, and in a different way. If your own report says ground glass rather than solid, that's not worse or better. It's a different track, and it's worth asking which track you're on.

And is there anything else on a report like that which should actually make her feel better? A word she might skim past at midnight without realising it was good news?

Calcified. If Helen's report had said calcified, or described a particular pattern of calcium in the spot, that's usually read as a sign the spot is harmless. In the Canadian study, a nodule was considered benign if it showed a benign calcification pattern, like being fully calcified. Hers doesn't say that, so it doesn't apply to her. But for somebody listening who's got their own report open, it's one of the words that usually means relax. A lot of what's on these reports is neutral. It just doesn't read that way to someone who's frightened.

So say Helen goes for the optional scan in a year. What is anyone actually looking for when they compare the two?

Change. That's all. The scan in a year is a comparison, not a fresh look. So the radiologist puts the two pictures side by side and asks one question. Is it the same? Because a cancer grows, and the harmless things mostly don't. Time is the test. In the Canadian study, a nodule was also counted as benign if the size of a solid nodule was unchanged for at least two years. So a spot that sits still is giving you information every month it does nothing. Helen's spot doing absolutely nothing is the result she wants. And the year in between isn't a delay before an answer. It's part of the answer.

But a year's a long time to sit with something. And Helen's already lost three nights' sleep. What does waiting actually do to people?

It can be hard. And it's been looked at directly. The focus-group researchers we mentioned at the start talked to people whose nodules were being watched. People whose doctors didn't discuss the actual cancer risk, or didn't explain the plan, experienced confusion and distress that sometimes lasted for months. Months. Not because of the nodule. Because nobody explained it. And the same researchers point out that although most nodules are benign, it may take two to three years to rule out cancer. So for people being followed, this isn't a week of worry. It can be a background hum that goes on for a long time. And the waiting is the part that depends most on the conversation she has, rather than the scan she has.

So the conversation's doing as much work as the scan. What did those patients say actually helped? Because that's the bit Helen can use tomorrow.

Three things, and none of them cost anything. In that study, patients found it helpful when physicians used lay terms, showed the CT image, and quantified cancer risk. Plain words. The picture. And a number. That's the list. Not reassurance. Not being told to try not to worry. A number. And the flip side was just as clear. They resented medical jargon and dismissive language. And I'd put probably nothing in that second category. It's meant kindly. But it lands as a brush-off.

So if Helen's GP rings tomorrow and says it's probably nothing, what should she say back? She won't want to sound difficult.

She won't sound difficult. She'll sound like somebody who's read her own report, which she has. I'd have her ask for exactly the three things on that list. First, can you tell me in plain words what you think this is? Second, can I see the picture? Most people never ask, and it can be oddly calming to see how tiny the spot is next to a whole lung. And third, can you put a number on it? If the answer comes back as less than one in a hundred, Helen now knows that matches the published figure for a spot her size. She's being told the truth, in the form that actually helps.

And the scan-or-no-scan choice. How should she actually make it? Because being told it's up to you can feel like being handed homework you didn't ask for.

That's a fair complaint, so let's make it concrete. There are two reasonable Helens here. The first one hears how small the risk is, hears that the guidance calls a second scan optional, and thinks: good, I'm done. She'd rather not have the radiation, or the next appointment, or the weeks waiting for a letter. That's a completely reasonable choice. But the second Helen hears exactly the same numbers. And she knows herself well enough to know the question will sit in her chest all year unless somebody looks. So she'd rather have one more scan, see that the spot hasn't moved, and close the file. That's reasonable too. Both of them are inside the guidance. What neither should do is pick by guessing what the doctor wants to hear. And what neither should do is ask for a scan every three months to keep the worry quiet. More looking doesn't make a five millimetre spot any safer. It just makes more appointments. And more letters. And more nights like the first one.

But what if her nodule had been bigger? Somebody listening might have a seven or a ten on their report, not a five.

Then the plan steps up. The JAMA review says nodules that are six to eight millimetres can be followed with a repeat chest CT in six to twelve months, depending on risk factors, the look of the spot, and patient preferences. So still watching. Just sooner. At eight millimetres and above, the options widen to more imaging, a PET scan, a biopsy, or surgery, and which one depends on the estimated chance it's cancer, the person's other health problems, and again what they prefer. It's still a judgement, not a conveyor belt. And the same three questions still apply.

Is there anything that would change Helen's plan in the meantime? Something she should watch for, so she isn't just sitting there waiting for a letter?

This is where I don't want to invent a checklist. So I'll stick to the guidance itself. But there are some situations where the small-nodule rules simply don't apply. The review that sets out the Fleischner rules says they shouldn't be used in patients with a recent history of cancer, because of the higher risk that a new spot is a spread from it, or in people with a weakened immune system, where infections are more likely. And they're not meant for lung screening programmes, which use their own system. So if Helen had a cancer recently, or she's on drugs that damp down her immune system, she should say so. Those aren't reasons to panic. They're reasons the default rule might not be her rule.

Screening, then, because you've mentioned it a few times. Helen used to smoke. Should she actually be in a screening programme now? Is that the real question hiding in all this?

It might be. And it's a good one to raise. But it's a separate question from the nodule, and it depends on where she lives. The clearest published rule is the American one. The US task force recommends annual screening for lung cancer with low-dose CT in adults aged fifty to eighty years who have a twenty pack-year smoking history and currently smoke or have quit within the past fifteen years. Pack-years are packs a day multiplied by years smoked. And that last part matters for Helen. She stopped more than twenty years ago. So under that rule she'd be outside it, however much she used to smoke. But other countries run their own programmes with their own rules, and I won't guess at those. So the useful move is a direct question to her GP. Given my history, am I eligible for lung screening where I live?

So the nodule doesn't automatically make her a screening patient. And if she were in screening, that wouldn't change anything we've said about this particular spot?

Not this spot, no. The spot gets managed on its own terms. And screening is a different question. It's whether somebody with her history should be scanned every year from now on, to look for new things. One more thing about her smoking. She stopped. Years ago. And the task force bases risk on age, total cumulative exposure to tobacco smoke, and years since quitting smoking. Years since quitting. She can't undo the years she smoked. But the clock she started when she quit has been running in her favour ever since.

And it's not only screening, is it? Because I'd guess all this talk about the harms of looking makes some people think scans are a bad idea altogether.

And that would be the wrong lesson. Looking saves lives in the right people. In the American trial, screening high-risk smokers with low-dose CT produced a relative reduction in mortality from lung cancer of twenty per cent. That's a real benefit, and it's why screening exists. The point is that every scan is a trade, and the trade looks different for different people. For a heavy smoker in their sixties, a yearly scan can find a cancer early. For Helen's five millimetre spot, the trade is much closer, which is why the second scan is optional.

Let's go back to the night she read the report. What was actually wrong with that moment?

Mostly the order things happened in. She got the information before she got the explanation. The report was written for her doctor, not for her. It's shorthand. Precise for another clinician, and frightening for everybody else. Solid. Nodule. Lobe. Every one of those words is neutral. And every one of them sounds like a diagnosis at eleven at night. Then there's the gap. Days, sometimes, between a report landing in an app and anybody ringing. That gap is where the search engine lives. And the search engine doesn't know her spot is five millimetres. It just knows the word lung and the word nodule. And nothing it shows her was written for her either.

Does she tell anybody? Her kids, her sister? Because I can imagine her not wanting to frighten anyone over something that's probably nothing.

That's her call, and there's no right answer. Remember what made the distress last, in that study. It wasn't the nodule. It was nobody explaining it. Some of that's down to doctors. And some of it's just being on your own with a word. So if telling her sister means she has somebody to say the number out loud to, that's worth a lot. And she can tell it the way we've told it. They found a tiny spot by accident. It's five millimetres. The chance it's anything is under one in a hundred. I'm talking to my GP about whether to look again in a year. That's a very different story from saying I've got something on my lung. Same facts. Completely different week.

Same facts, completely different week. So if somebody listening is in that gap right now — report in the app, nobody's rung — what should they do tonight?

Find the size first. It'll be in the report, usually in millimetres. That one number tells you more than any page you'll find online. If it's under six millimetres, you're in the group where the published probability of cancer is less than one in a hundred. Then look for the word solid, or ground glass, or part solid, because those take different tracks and your doctor can tell you which one you're on. And then put the phone down. I mean that. Nothing on the internet tonight will change the plan. What will change the plan? The conversation. And that conversation goes better if you bring three questions instead of a fear. What do you think this is, in plain words? Can I see it? And what's the number?

Before we finish, what don't we know? Because you've been careful the whole way through, and I'd like you to draw the line.

The first gap is that a lot of the numbers come from people who aren't Helen. The Canadian model and the American trial both studied people at high risk who'd signed up for screening. But Helen found hers by accident, during a kidney scan. And the Fleischner guidance itself says it represents the consensus of the society, the opinions of a multidisciplinary international group of specialists. But it means the less than one in a hundred figure is an estimate pulled together from several kinds of evidence, not a measurement taken on people exactly like her. And the second gap is the waiting. We know uncertainty is hard on people, and we know explanation helps. What I couldn't find is good evidence on whether a second scan leaves people like Helen calmer or more anxious over the long run. It probably depends on the person, which is exactly why the choice is left with her. And the third is the thing nobody can give her. Certainty. At five millimetres, nobody can promise her it's nothing. What they can do is tell her how small the chance is, and what the plan is. And that turns out to be most of what people need.

If Helen takes one thing from this, what is it? The thing she says to herself at eleven o'clock tonight, when she picks up the phone again.

That the word on the report was scarier than the thing on the scan. A five millimetre nodule is small. It's common. And almost all of them are nothing. And the guidance for her size is mostly about whether to look again at all. And she gets a say in that. That's a much better place to be.

And three things to take to her doctor. The ones she writes down before the phone call, so she doesn't forget them halfway through.

First. Am I in the low-risk group or the high-risk group for this, and why? Because that decides whether a scan in a year is even on the table. Second. Can you show me the scan, and tell me in plain words what you think the spot is? Ask to see it. And third. Given my smoking history, should I be in a lung screening programme where I live? That one's about her future, not about this spot. And it's the question most likely to get missed when everybody's focused on the nodule. Three questions. One phone call. And then, with any luck, some sleep.